605177 东亚药业
已收盘 03-20 15:00:00
资讯
新帖
简况
股市必读:东亚药业(605177)3月19日收盘跌6.73%,主力净流入305.03万元
证券之星 · 03-20 02:26
股市必读:东亚药业(605177)3月19日收盘跌6.73%,主力净流入305.03万元
东亚药业(605177)3月10日股东户数1.02万户,较上期减少0.92%
证券之星 · 03-16
东亚药业(605177)3月10日股东户数1.02万户,较上期减少0.92%
东亚药业(605177.SH):沙格列汀二甲双胍缓释片获药品注册证书
智通财经 · 03-16
东亚药业(605177.SH):沙格列汀二甲双胍缓释片获药品注册证书
每周股票复盘:东亚药业(605177)股东户数增1.09%,达1.03万户
证券之星 · 03-15
每周股票复盘:东亚药业(605177)股东户数增1.09%,达1.03万户
东亚药业(605177)2月28日股东户数1.03万户,较上期增加1.09%
证券之星 · 03-09
东亚药业(605177)2月28日股东户数1.03万户,较上期增加1.09%
每周股票复盘:东亚药业(605177)股东户数增3.73%,富马酸伏诺拉生片获批
证券之星 · 03-08
每周股票复盘:东亚药业(605177)股东户数增3.73%,富马酸伏诺拉生片获批
东亚药业(605177)披露富马酸伏诺拉生片获得药品注册证书,3月5日股价上涨1.4%
证券之星 · 03-05
东亚药业(605177)披露富马酸伏诺拉生片获得药品注册证书,3月5日股价上涨1.4%
东亚药业(605177.SH):富马酸伏诺拉生片获得药品注册证书
智通财经 · 03-04
东亚药业(605177.SH):富马酸伏诺拉生片获得药品注册证书
东亚药业(605177)2月10日股东户数1.02万户,较上期增加3.73%
证券之星 · 03-02
东亚药业(605177)2月10日股东户数1.02万户,较上期增加3.73%
东亚药业(605177)披露2025年度业绩预亏公告,2月24日股价上涨2.67%
证券之星 · 02-24
东亚药业(605177)披露2025年度业绩预亏公告,2月24日股价上涨2.67%
每周股票复盘:东亚药业(605177)2025年净利预亏7500万至9000万元
证券之星 · 02-15
每周股票复盘:东亚药业(605177)2025年净利预亏7500万至9000万元
东亚药业(605177)披露回购注销部分限制性股票公告,2月6日股价上涨1.26%
证券之星 · 02-06
东亚药业(605177)披露回购注销部分限制性股票公告,2月6日股价上涨1.26%
东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%
证券之星 · 02-02
东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%
原料药龙头东亚药业预亏近亿,转型之路仍崎岖
新浪证券 · 01-30
原料药龙头东亚药业预亏近亿,转型之路仍崎岖
每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿
证券之星 · 01-25
每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿
东亚药业去年预亏或高达9000万元,转型效果未达预期
新京报 · 01-23
东亚药业去年预亏或高达9000万元,转型效果未达预期
东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元
智通财经 · 01-22
东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元
每周股票复盘:东亚药业(605177)预计2025年净利润为负值
证券之星 · 01-18
每周股票复盘:东亚药业(605177)预计2025年净利润为负值
东亚药业最新公告:预计2025年净利润亏损
证券之星 · 01-14
东亚药业最新公告:预计2025年净利润亏损
东亚药业跌3.55% 2020年上市2募资共15.74亿
中金财经 · 01-12
东亚药业跌3.55% 2020年上市2募资共15.74亿
加载更多
公司概况
公司名称:
浙江东亚药业股份有限公司
所属行业:
医药制造业
上市日期:
2020-11-25
主营业务:
浙江东亚药业股份有限公司的主营业务是化学原料药、医药中间体的研发、生产和销售。公司的主要产品是头孢克洛原料药、头孢克洛中间体、美罗培南钠中间体、马来酸曲美布汀原料药和中间体、左氧氟沙星原料药及中间体、盐酸左氧氟沙星、噻康唑原料药、盐酸特比萘芬原料药、卢立康唑原料药、非布司他原料药。公司是浙江省专利示范企业,并多次承担省级重大科技专项、国家火炬计划项目、省重大国际科技专项、省重点高新技术产品开发项目等。公司“β-内酰胺类药物创新团队”于2014年入选台州市重点企业技术创新团队,多次获得浙江省和台州市科技进步奖等。报告期内,公司全资子公司杭州善礼获得中国合格评定国家认可委员会(CNAS)实验室认可证书。
发行价格:
31.13
{"stockData":{"symbol":"605177","market":"SH","secType":"STK","nameCN":"东亚药业","latestPrice":20.41,"timestamp":1773990001000,"preClose":21.19,"halted":0,"volume":2572000,"delay":0,"changeRate":-0.0368,"floatShares":112999999,"shares":114999999,"eps":-1.9023,"marketStatus":"已收盘","change":-0.78,"latestTime":"03-20 15:00:00","open":21.5,"high":21.57,"low":20.31,"amount":53689200,"amplitude":0.0595,"askPrice":20.42,"askSize":4,"bidPrice":20.41,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-1.9023,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"adjPreClose":21.19,"symbolType":"stock","openAndCloseTimeList":[[1773970200000,1773977400000],[1773982800000,1773990000000]],"highLimit":23.31,"lowLimit":19.07,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":114726119,"isCdr":false,"pbRate":1.38,"roa":"--","roe":"--","epsLYR":-0.9,"committee":-0.066148,"marketValue":2342000000,"turnoverRate":0.0228,"status":1,"floatMarketCap":2298000000},"requestUrl":"/m/hq/s/605177","defaultTab":"news","newsList":[{"id":"2620127365","title":"股市必读:东亚药业(605177)3月19日收盘跌6.73%,主力净流入305.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620127365","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620127365?lang=zh_cn&edition=full","pubTime":"2026-03-20 02:26","pubTimestamp":1773944772,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘,东亚药业报收于21.19元,下跌6.73%,换手率3.24%,成交量3.65万手,成交额7907.67万元。来自资金流向:主力资金净流入305.03万元,占总成交额3.86%。交易信息汇总股价提醒3月19日东亚药业收盘报21.19元,跌6.73%,当日成交365.28万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000002169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2619455029","title":"东亚药业(605177)3月10日股东户数1.02万户,较上期减少0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619455029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619455029?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:13","pubTimestamp":1773652388,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2026年3月10日公司股东户数为1.02万户,较2月28日减少95.0户,减幅为0.92%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至3月10日,化学制药行业平均股东户数为3.42万户。从股价来看,2026年2月28日至2026年3月10日,东亚药业区间跌幅为0.87%,在此期间股东户数减少95.0户,减幅为0.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600023324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2619430963","title":"东亚药业(605177.SH):沙格列汀二甲双胍缓释片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619430963","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619430963?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:38","pubTimestamp":1773646695,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东亚药业(605177.SH)公告,公司收到国家药品监督管理局核准签发的沙格列汀二甲双胍缓释片(I)、(III)的《药品注册证书》。沙格列汀二甲双胍缓释片配合饮食和运动治疗,适用于正在接受沙格列汀和二甲双胍治疗的2型糖尿病成人患者,以改善此类患者的血糖控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东亚药业(605177.SH):沙格列汀二甲双胍缓释片获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2619785851","title":"每周股票复盘:东亚药业(605177)股东户数增1.09%,达1.03万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2619785851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619785851?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:49","pubTimestamp":1773514148,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,东亚药业报收于22.6元,较上周的22.95元下跌1.53%。本周,东亚药业3月13日盘中最高价报23.28元。本周关注点股本股东变化:股东户数较上期增加1.09%,达1.03万户股本股东变化:户均持股数量由1.12万股降至1.11万股股本股东变化:户均持股市值为25.49万元股本股东变化股东户数变动截至2026年2月28日,东亚药业股东户数为1.03万户,较2月10日增加111.0户,增幅1.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2618415836","title":"东亚药业(605177)2月28日股东户数1.03万户,较上期增加1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618415836","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618415836?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:11","pubTimestamp":1773047483,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2026年2月28日公司股东户数为1.03万户,较2月10日增加111.0户,增幅为1.09%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至2月28日,化学制药行业平均股东户数为3.43万户。从股价来看,2026年2月10日至2026年2月28日,东亚药业区间涨幅为5.04%,在此期间股东户数增加111.0户,增幅为1.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900022834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2617866663","title":"每周股票复盘:东亚药业(605177)股东户数增3.73%,富马酸伏诺拉生片获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2617866663","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617866663?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:36","pubTimestamp":1772908574,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,东亚药业报收于22.95元,较上周的22.94元上涨0.04%。本周,东亚药业3月6日盘中最高价报23.07元。本周关注点股本股东变化:股东户数较前期增长3.73%,户均持股数量下降至1.12万股。股本股东变化股东户数变动截至2026年2月10日,公司股东户数为1.02万户,较1月31日增加367.0户,增幅为3.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2617517142","title":"东亚药业(605177)披露富马酸伏诺拉生片获得药品注册证书,3月5日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517142","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517142?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:23","pubTimestamp":1772702601,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘,东亚药业报收于21.68元,较前一交易日上涨1.4%,最新总市值为24.87亿元。东亚药业于近日披露《关于富马酸伏诺拉生片获得药品注册证书的公告》。公告显示,公司收到国家药监局核准签发的富马酸伏诺拉生片《药品注册证书》,批准该公司生产规格为10mg和20mg的富马酸伏诺拉生片,注册分类为化学药品4类。目前已有包括四川科伦药业、齐鲁制药在内的多家企业获得该药品注册证书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500028069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2616858763","title":"东亚药业(605177.SH):富马酸伏诺拉生片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616858763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616858763?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:03","pubTimestamp":1772611396,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东亚药业(605177.SH)发布公告,近日,公司收到国家药品监督管理局核准签发的富马酸伏诺拉生片的《药品注册证书》,富马酸伏诺拉生是一种钾离子竞争性酸阻滞剂(简称P-CAB),可以抑制胃酸的生成和抑制胃肠道上部粘膜损伤,主要用于治疗胃食管反流,与适当的抗生素联用以根除幽门螺杆菌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2616387529","title":"东亚药业(605177)2月10日股东户数1.02万户,较上期增加3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387529","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616387529?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:26","pubTimestamp":1772443587,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2026年2月10日公司股东户数为1.02万户,较1月31日增加367.0户,增幅为3.73%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至2月10日,化学制药行业平均股东户数为3.42万户。从股价来看,2026年1月31日至2026年2月10日,东亚药业区间涨幅为1.91%,在此期间股东户数增加367.0户,增幅为3.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200025188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2613977437","title":"东亚药业(605177)披露2025年度业绩预亏公告,2月24日股价上涨2.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613977437","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613977437?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:49","pubTimestamp":1771930153,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,东亚药业报收于22.3元,较前一交易日上涨2.67%,最新总市值为25.58亿元。该股当日开盘21.89元,最高22.67元,最低21.89元,成交额达4724.81万元,换手率为1.89%。近日,东方金诚国际信用评估有限公司发布关于浙江东亚药业股份有限公司2025年度业绩预亏的关注公告。东亚药业预计2025年度归属于上市公司股东的净利润为-9000万元到-7500万元,扣除非经常性损益后的净利润为-10200万元到-8700万元。东方金诚将持续关注公司经营与财务状况变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2611673145","title":"每周股票复盘:东亚药业(605177)2025年净利预亏7500万至9000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611673145","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611673145?lang=zh_cn&edition=full","pubTime":"2026-02-15 02:11","pubTimestamp":1771092670,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,东亚药业报收于21.72元,较上周的21.76元下跌0.18%。本周,东亚药业2月13日盘中最高价报22.24元。东亚药业当前最新总市值24.92亿元,在化学制药板块市值排名144/150,在两市A股市值排名4982/5189。本周关注点公司公告汇总:东亚药业预计2025年净利润亏损7500万元至9000万元。东亚药业预计2025年度归属于上市公司股东的净利润为-9000万元到-7500万元,扣除非经常性损益后的净利润为-10200万元到-8700万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2609059148","title":"东亚药业(605177)披露回购注销部分限制性股票公告,2月6日股价上涨1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609059148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609059148?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:18","pubTimestamp":1770387505,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,东亚药业报收于21.76元,较前一交易日上涨1.26%,最新总市值为24.96亿元。该股当日开盘21.31元,最高22.05元,最低21.31元,成交额达4548.59万元,换手率为1.85%。近日,东亚药业发布《关于回购注销部分激励对象已获授但尚未解除限售的限制性股票的公告》。本次回购注销不会对公司的财务状况和经营成果产生重大影响,已获得2024年第三次临时股东大会授权,无需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600041012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2608385220","title":"东亚药业(605177)1月31日股东户数0.98万户,较上期减少1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608385220?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:43","pubTimestamp":1770025425,"startTime":"0","endTime":"0","summary":"证券之星消息,近日东亚药业披露,截至2026年1月31日公司股东户数为9845.0户,较1月20日减少145.0户,减幅为1.45%。在化学制药行业个股中,东亚药业股东户数低于行业平均水平,截至1月31日,化学制药行业平均股东户数为3.42万户。从股价来看,2026年1月20日至2026年1月31日,东亚药业区间涨幅为5.05%,在此期间股东户数减少145.0户,减幅为1.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200025809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2607109930","title":"原料药龙头东亚药业预亏近亿,转型之路仍崎岖","url":"https://stock-news.laohu8.com/highlight/detail?id=2607109930","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607109930?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:53","pubTimestamp":1769755980,"startTime":"0","endTime":"0","summary":" 近日,东亚药业发布2025年度业绩预告,预计全年净亏损7500万元至9000万元。尽管亏损幅度较上年有所收窄,但公司仍未能摆脱业绩持续下滑的困境。作为一家以抗菌药原料药为主业的药企,东亚药业在政策收紧、行业竞争加剧等多重压力下,正尝试通过“原料药制剂一体化”战略突围。然而,从业绩表现和转型进展来看,这条转型之路并不平坦。 面对行业环境的深刻变化,东亚药业的转型已势在必行,但道路依然漫长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-01-30/doc-inhkakfp0636110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2606498232","title":"每周股票复盘:东亚药业(605177)2025年扣非净利预亏8700万至1.02亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2606498232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606498232?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:54","pubTimestamp":1769280850,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,东亚药业报收于22.83元,较上周的20.72元上涨10.18%。本周,东亚药业1月22日盘中最高价报23.5元,股价触及近一年最高点。东亚药业当前最新总市值26.19亿元,在化学制药板块市值排名143/150,在两市A股市值排名4915/5182。业绩披露要点东亚药业发布业绩预告,预计2025年全年扣非后净利润亏损8700万元至1.02亿元。公司公告汇总浙江东亚药业预计2025年度归属于上市公司股东的净利润为-9,000万元到-7,500万元,扣除非经常性损益后为-10,200万元到-8,700万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177","BK0239"],"gpt_icon":0},{"id":"2605472835","title":"东亚药业去年预亏或高达9000万元,转型效果未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2605472835","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605472835?lang=zh_cn&edition=full","pubTime":"2026-01-23 19:44","pubTimestamp":1769168640,"startTime":"0","endTime":"0","summary":"1月23日,浙江东亚药业股份有限公司发布2025年业绩预告,预计实现归属于上市公司股东的净亏损为9000万元到7500万元,上年同期为净亏损1.01亿元;预计实现归属于上市公司股东的扣除非经常性损益的净亏损为1.02亿元到8700万元,上年同期为净亏损9840.82万元。上述情况导致东亚药业报告期营业收入较上年度下滑,毛利额同比减少1.08亿元。抗菌药市场压缩,业绩下滑近年来,东亚药业业绩持续承压。","market":"us","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261231920192880149.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/1/wangl8820261231920192880149.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1769168685168036.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1769168685168036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2605465793","title":"东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605465793","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605465793?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:22","pubTimestamp":1769070169,"startTime":"0","endTime":"0","summary":"智通财经APP讯,东亚药业(605177.SH)发布2025年度业绩预告,预计2025年度实现归属于上市公司股东的净亏损7,500万元至9,000万元。报告期内,公司原料药及制剂陆续新申报了一批批件。其中获得了左氧氟沙星片的批件,为公司获批的首个制剂批件,标志着公司原料药制剂一体化发展战略取得重大突破,将进一步丰富公司产品线,有助于提升公司竞争力,促进公司持续、稳定、健康地发展。同时为公司后续制剂注册证书申报积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"东亚药业(605177.SH)发预亏,预计2025年度归母净亏损7500万元至9000万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","605177"],"gpt_icon":0},{"id":"2604792529","title":"每周股票复盘:东亚药业(605177)预计2025年净利润为负值","url":"https://stock-news.laohu8.com/highlight/detail?id=2604792529","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604792529?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:24","pubTimestamp":1768681449,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,东亚药业报收于20.72元,较上周的21.11元下跌1.85%。本周,东亚药业1月14日盘中最高价报21.65元。东亚药业当前最新总市值23.77亿元,在化学制药板块市值排名147/150,在两市A股市值排名4972/5183。股本股东变化股东户数变动截至2026年1月10日,东亚药业股东户数为1.03万户,较12月31日减少258户,减幅2.43%。业绩披露要点业绩预告东亚药业发布业绩预告,预计2025年全年归属净利润为负值,2025年度经营业绩将出现亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177"],"gpt_icon":0},{"id":"2603698965","title":"东亚药业最新公告:预计2025年净利润亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2603698965","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603698965?lang=zh_cn&edition=full","pubTime":"2026-01-14 15:41","pubTimestamp":1768376506,"startTime":"0","endTime":"0","summary":"东亚药业(605177.SH)公告称,预计2025年度归属于上市公司股东的净利润为负值,经营业绩将出现亏损。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400020788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605177"],"gpt_icon":0},{"id":"2602356518","title":"东亚药业跌3.55% 2020年上市2募资共15.74亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2602356518","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602356518?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:23","pubTimestamp":1768209784,"startTime":"0","endTime":"0","summary":"中国经济网北京1月12日讯 东亚药业 今日股价下跌,截至收盘,报20.36元,跌幅3.55%。目前该股处于破发状态。 东亚药业于2020年11月25日在上交所主板上市,发行价格为31.13元/股。2021年2月8日,东亚药业盘中跌破发行价。 东亚药业发行费用合计1.02亿元,其中,保荐机构东兴证券股份有限公司获得保荐及承销费用6143.87万元。 经计算,公司上市以来共募资2次,共计15.74亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260112/31934706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","605177"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774174096768,"stockEarnings":[{"period":"1week","weight":-0.0969},{"period":"1month","weight":-0.0603},{"period":"3month","weight":0.0979},{"period":"6month","weight":0.0586},{"period":"1year","weight":0.0185},{"period":"ytd","weight":0.1466}],"compareEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.0171},{"period":"6month","weight":0.0359},{"period":"1year","weight":0.1608},{"period":"ytd","weight":-0.003}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江东亚药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10228人(较上一季度减少0.92%)","perCapita":"11007股","listingDate":"2020-11-25","address":"浙江省台州市三门县浦坝港镇沿海工业城","registeredCapital":"11472万元","survey":" 浙江东亚药业股份有限公司的主营业务是化学原料药、医药中间体的研发、生产和销售。公司的主要产品是头孢克洛原料药、头孢克洛中间体、美罗培南钠中间体、马来酸曲美布汀原料药和中间体、左氧氟沙星原料药及中间体、盐酸左氧氟沙星、噻康唑原料药、盐酸特比萘芬原料药、卢立康唑原料药、非布司他原料药。公司是浙江省专利示范企业,并多次承担省级重大科技专项、国家火炬计划项目、省重大国际科技专项、省重点高新技术产品开发项目等。公司“β-内酰胺类药物创新团队”于2014年入选台州市重点企业技术创新团队,多次获得浙江省和台州市科技进步奖等。报告期内,公司全资子公司杭州善礼获得中国合格评定国家认可委员会(CNAS)实验室认可证书。","listedPrice":31.13},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东亚药业,605177,东亚药业股票,东亚药业股票老虎,东亚药业股票老虎国际,东亚药业行情,东亚药业股票行情,东亚药业股价,东亚药业股市,东亚药业股票价格,东亚药业股票交易,东亚药业股票购买,东亚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}